ML-SYS / 2026.07NON-CLINICAL RESEARCH MATERIALSORIGIN DECLARED BY LOT

← Compound index

RM-TRS / Tissue, repair and matrix signalling

ABP-7

Also known as: Actin-binding peptide-7 · TB-500 fragment 17-23 · Ac-LKKTETQ

Preclinical evidence

Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.

What this is

ABP-7 is the N-acetylated LKKTETQ segment corresponding to residues 17-23 of thymosin beta-4. It must not be represented as full-length thymosin beta-4 or inherit every finding attached to the parent peptide.

Evidence position

Direct analytical, cell and animal records support Grade C. The evidence is preclinical and sequence-specific.

What the record does not establish

The record does not establish a human outcome, an approved use or the identity, purity and quantity of a supplier lot.

Sources

  • 01
    Identification of Ac-LKKTETQ in a market TB-500 samplePubMed
    Shows
    Mass-spectrometric identification and synthesis of the N-acetylated 17-23 fragment
    Does not show
    Analytical identity study; not an efficacy or safety study
  • 02
    Actin-binding domain in dermal wound modelsPubMed
    Shows
    The LKKTETQ fragment was studied in aged-mouse wound repair
    Does not show
    Animal model; the paper does not establish human outcomes
  • 03
    Thymosin beta-4 active-site reviewPubMed
    Shows
    Maps the LKKTETQ sequence to the central actin-binding region
    Does not show
    Review-level mechanism context, not an independent human trial
  • 04
    ABP-7 market listingCore Peptides
    Shows
    Current research-market use of the ABP-7 and Ac-LKKTETQ names
    Does not show
    Supplier copy is not independent evidence or lot verification

External database index

LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE

Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.

PUBMED / FOUND RECORDS

  1. Biological activities of thymosin beta4 defined by active sites in short peptide sequences.FASEB journal : official publication of the Federation of American Societies for Experimental Biology / 2010 JulPMID 20179146 / DOI 10.1096/fj.09-142307
  2. Alkaline Phosphatase-Triggered Spatiotemporal Repair of Corneal Injury with TB500 Peptide Hydrogel.ACS applied materials & interfaces / 2025 Dec 17PMID 41359360 / DOI 10.1021/acsami.5c14652
  3. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences / 2024 Mar 1PMID 38382158 / DOI 10.1016/j.jchromb.2024.124033
  4. Thymosin β4 inhibits PDGF-BB induced activation, proliferation, and migration of human hepatic stellate cells via its actin-binding domain.Expert opinion on biological therapy / 2018 JulPMID 30063851 / DOI 10.1080/14712598.2018.1478961
  5. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry.Journal of chromatography. A / 2012 Nov 23PMID 23084823 / DOI 10.1016/j.chroma.2012.09.043

Related compounds

RM-TRS

Thymosin Beta 4

Read entry →
RM-TRS

TB-500

Read entry →